E-DRUG: Affordable prescription drugs Act (USA) (2)
---------------------------------------------------
Hello: This all sounds quite rational, but certainly raises some questions
about its impact. For example, if a product is patented, R&D carried out,
and the product is approved, isn't the process some ten to twelve years on
average, today? If so, then the patent life, or market exclusivity period,
effectively only about four to five years for a company to enjoy such
exclusivity?
If so, and the specific product must be required to be licensed to generic
firms, can't we "assume" negotiations might just take several years, thus
nullifying the impact of this legislation? And to the benefit of whom?
Seems to me, maybe such scenarios should have been raised and considered
prior to proposing this legislation. There are solutions and answers to
the issues addressed in this legislation, and I for one, would like to see
those solutions and answers recognized and acknowledged. Thanks for
bringing this press release to this list, Jamie. I appreciate it.
Thanks,
Tom
Thomas A. Poe, M.D., Director
The World Center For Clinical Research
2044 Plumas Street Reno, NV 89509-3708
Phone: 775-829-1799
admin@worldccr.org http://worldccr.org
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.